Clinical trial
Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating…
NCT00227682 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00227682 |
|---|---|
| Title | Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase II Study of Arsenic Trioxide in Combination With Thalidomide, Dexamethasone, and Ascorbic Acid |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Dietary Supplement, Drug |
| Interventions | ascorbic acid, arsenic trioxide, dexamethasone, thalidomide |
| Enrollment | 2 |
| Start date | Jun 1, 2004 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Sep 28, 2005 |
| Last update posted | May 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: